MAPT and Alzheimer disease: In a recent pilot study conducted on 12 DM1 and 2 AD patients, along with tau-PET imaging, Laforce et al. studied (i) CSF concentrations of Ab42, Ab40, T-tau, and P-tau by an automated chemiluminescent enzyme-immunoassay, (ii) plasma concentrations of Ab42 and Ab40 by a multiplex xMAP technique with a LABScan-200 system, and (iii) plasma concentrations of T-tau, Glial Fibrillary Acidic Protein (GFAP), and Neurofilament Light Chain (NfL) by single molecule array (SiMoA) [31].